Bayer receives FDA approval for lower dose formulation of ANGELIQ

[News]

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus.

More... (http://www.news-medical.net/news/20120229/Bayer-receives-FDA-approval-for-lower-dose-formulation-of-ANGELIQ.aspx)